Clinical Trial Update: Extension Study of Semapimod 60 mg IV x 3 Days [Phase 2]

View source ↗

Summary

Phase 2 extension study update for semapimod IV in Crohn's disease; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Semapimod (CNI-1493)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED